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Background: The inhibitor of differentiation/DNA binding protein family (Id1-4) is involved 
in cell cycle control, tumorigenesis and angiogenesis through the negative regulation of he-
lix-loop-helix transcription factors.  Of these proteins, Id4 is known to play an important role 
in neural stem cell differentiation, and deregulation has been implicated in glial neoplasia.  
However, the expression and significance of Id4 in astrocytomas has not been fully addressed.  
Herein we report the differential expression of Id4 in astrocytomas of various grades using 
tissue microarrays (TMA) and immunohistochemistry (IHC). 
Design: The GBM TMA was constructed from 53 archival cases at Georgetown University 
Hospital and a TMA with normal brain controls and grades II-III astrocytoma was obtained 
from Cybrdi (Rockville, MD). TMA sections were stained with Id4 antibody and the slides 
were scored according to the percentage of staining astrocytic nuclei (<9% -, 10-50% +, >51% 
++). The Fisher Exact test was used to test for statistical significance. 
Results: Nuclear staining for Id4 was seen in 73.58% GBMs, 25% grade III, and 12.5% grade II 
astrocytomas; staining was absent in normal brain tissue. There was a statistically significant 
difference between GBM and grades II, III astrocytoma (p <0.01).  Significant Id4 expression 
was not detected in normal brain. 
Conclusions: Our study confirms the frequent upregulation of Id4 expression in GBM, which 
lends support to its role in tumorigenesis, possibly in the transformation of low to high-grade 
astrocytoma (i.e. GBM).  Further studies are warranted to determine the precise role of Id4 in 
glial neoplasia and its potential use in targeted therapy for GBM.  
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Introduction 
Diffuse astrocytomas, World Health Organiza-
tion (WHO) grades II-IV, are the most common pri-
mary brain tumors in adults [1].  Glioblastoma (grade 
IV), which comprises the majority, has a dismal 
prognosis with less than half of patients surviving 
more than one year.  Early and extensive infiltration 
of neoplastic cells beyond their gross and radio-
graphic appearance is a critical factor that limits the 
efficacy of surgery [2].  With rare exceptions, standard 
radio/chemotherapeutic regimens have been unable 
to obtain sustainable cures.  Effective treatment of 




challenge and there is an urgent need for new thera-
pies targeting the molecular and cellular mechanisms 
that mediate tumor growth.   
Complex multigenetic pathways have been 
identified in the oncogenesis, progression, and main-
tenance of astrocytic brain tumors.  Novel therapies 
that have the potential for overcoming limitations 
associated with currently available drugs are now in 
varying phases of clinical development [3].  Despite 
recent progress, major challenges remain in clarifying 
the biology of astrocytic tumors and translating basic 
research advances into effective therapies. 
The inhibitor of differentiation protein family is 
involved in cell cycle control, tumor genesis and an-
giogenesis through the negative regulation of he-
lix-loop-helix transcription factors [4-6].  To date, four 
structurally similar proteins (Id1-4) have been cha-
racterized that perform different regulatory functions 
during development, and when deregulated, during 
oncogenesis [7-11].  Of these proteins, Id4 has been 
reported to participate in neural stem cell differentia-
tion, induce apoptosis in astrocytic cultures, promote 
angiogenesis, and drive brain tumor genesis through 
notch signaling [12-16].  However, the precise role and 
clinical relevance of Id4 in the formation and pro-
gression of gliomas remains elusive.  Herein we re-
port the differential expression of Id4 in astrocytomas 
of various grades including GBM using tissue micro-
arrays (TMA) and immunohistochemistry (IHC) and 
discuss its possible role in astrocytoma oncogenesis. 
Materials and Methods 
This retrospective study consists of 53 cases of 
surgically resected GBM that were retrieved from the 
files of the Department of Pathology, Georgetown 
University Medical Center.  All cases were reviewed 
and classified according to the 2007 World Health 
Organization (WHO) classification system [1].  For 
study purposes, a tissue microarray (TMA) was ob-
tained from Cybrdi (Rockville, MD) that contained 
normal brain, and astrocytoma (grades II, III) tissue 
cores.  Specifically, the array had a total of 32 cores 
with 8 grade II and 8 grade III astrocytomas, and 16 
cores of normal brain tissue. 
Glioblastoma tissue microarray construction 
Areas showing the histopathologic features of 
GBM were selected on archival H&E slides, and then, 
representative areas of tumor were marked on the 
corresponding paraffin block for TMA construction.  
Briefly, after the tissue cylinders were taken from the 
selected regions of the donor paraffin block, they were 
then punched precisely into a recipient paraffin block 
using a tissue-arraying instrument.  Multiple sections 
(5 μm thick) were cut and mounted onto microscope 
slides.  An H&E stained section was made to confirm 
the presence of the original areas selected from each 
tumor.  The TMA sections were evaluated by two 
pathologists in a blinded fashion to validate the di-
agnostic morphology of each array spot.  All images 
were taken using an Olympus BX41 microscope. 
Immunohistochemistry 
TMA sections were stained with Id4 antibody 
(1:100, Chemicon International, Temecula, CA) using 
a DAKO autoimmunostainer and Envision Flex de-
tection system (DAKO, Carpinteria, CA).  The im-
munostaining pattern (i.e., cytoplasmic, nuclear, 
membranous) for Id4 were assessed by a semiquan-
titative method within the neoplastic cell and vascular 
components.  Adequate immunoreactive tissue sam-
ples were used as positive controls for each antibody.  
Negative controls were produced by omission of the 
primary antibody. 
Statistical analysis 
The Fisher exact test was carried out to evaluate 
the strength of association between the presence of 
Id4 staining and each tumor subset (glioblastoma, 
anaplastic astrocytoma, grade III and astrocytoma, 
grade II).  Values of P < 0.05 were considered statisti-
cally significant. 
Results 
Interpretation of immunohistochemical staining 
A summary of the immunohistochemical results 
is presented in Table 1.  
Table 1 Summary of Id4 Immunostaining results 
Diagnosis  No. of TMA cores % Nuclear staining 
Normal  16             0/16 (0%) 
Astrocytoma, grade II  8             1/8 (12.5%) 
Astrocytoma, grade III  8             2/8 (25.0%) 
Glioblastoma  53             39/53 (73.6%) 
 
The extent of staining was scored semiquantita-
tively by estimating the average percentage of stain-
ing nuclei in tumor cells (<9% = negative, 10-50% 
=positive, >51% ++).  Only cells with moderately in-
tense nuclear staining were interpreted as positive for 
Id4.  Significant cytoplasmic or membranous staining 
was not observed.  Neoplastic astrocytes in GBM 
showed intense nuclear immunoreactivity in 39 of 53 
(73.58%), whereas 2 of 8 (25%) grade III and 1 of 8 
(12.5%) of grade II astrocytomas showed staining 
(Figure 1).   





Figure 1. Immunohistochemical staining of Id4 protein in tissue microarray. Id4 expression correlates with astrocytoma 
grade. (a) normal brain tissue (H&E). (b) normal brain tissue lacks Id4 staining. (c) moderately cellular grade II astrocytoma 
with nuclear pleomorphism  (H&E).  (d) note scattered nuclei immunolabel for Id4 in grade II astrocytoma. (e) GBM (H&E) 
with marked nuclear pleomorphism and microvascular proliferation.  (f). widespread nuclear staining in GBM. 
 
Endothelial cell nuclei within tumor blood ves-
sels were devoid of significant Id4 labeling and only 
low-level background staining was seen in normal 
brain tissue cores (0/16).   
Statistical analysis 
There was a statistically significant difference 
between GBM and normal brain tissue, GBM and 
grade II, III astrocytoma (p <0.01).  No statistically 
significance was detected between normal brain tis-
sue, grade II and grade III astrocytoma (p>0.05). 
Discussion  
In this study, we documented a marked increase 
in expression of Id4 in GBM compared to low-grade 
astrocytoma.  While significant staining was not de-
tected in normal brain or in tumor blood vessels; we 
observed a potentially clinically relevant strong cor-
relation between the nuclear expression of Id4 and 
histological grade, with the highest expression seen in 
GBM (73.58%) and anaplastic astrocytoma (25%).  The 
commercially available anti-Human Id4 monoclonal 
antibody that was used in this study was developed 
in mice and appears suitable for use in formalin-fixed 
paraffin-embedded tissue.  Similar nuclear localiza-
tion of Id4 in tumor cells has been reported in 
high-grade prostate carcinoma and small cell lung 
carcinoma [17, 18].  The selective nuclear localization 
of Id4 in glial tumors contrasts with the dual cytop-
lasmic-nuclear expression of Id1-3.  Of note, Vande-
putte et al. demonstrated that Id1-3 displayed cytop-
lasmic as well as nuclear localization and that expres-
sion was positively correlated with proliferation in-
dices [19].   
It is not surprising that Id proteins are implicated 




versely with cell differentiation, it has been postulated 
that these proteins participate in the activation of 
transcription factors that stimulate reprogramming of 
the cells into cancer stem-like cells [11-12].  Along 
parallel lines, Marin-Hustegge detailed the complex 
role of Id4 as an oligodendrocyte differentiation inhi-
bitor with the ability to differentially regulate the ex-
pression and subcellular distribution of myelin gene 
products [20]. 
With respect to other members of the Id family, 
Id2 has been shown to mediate tumor initiation, pro-
liferation, and angiogenesis In Rb mutant mice [19].  
In humans, Id2 expression may play a role in the ma-
lignant progression of small cell lung carcinoma that 
may be prognostically significant [18].  Forootan et al. 
reported that Id-1 overexpression in prostate cancer 
was associated with reduced patient survival [22].   
Other investigators have identified a similar predic-
tive value for Id proteins in breast [23], colorectal [24] 
and bladder cancer [25], further underscoring their 
importance in neoplasia in multiple organs.   
Although the precise mechanism of Id4 in pro-
moting glial neoplasia remains incompletely charac-
terized, several mechanisms have emerged in recent 
studies.  Most recently, Kuzontkoski et al. reported 
that Id4 promotes angiogenesis and growth of GBM 
by elevating matrix GLA levels [14].  In an earlier 
study, Fontemaggi et al. identified Id4 as part of a 
transcriptional axis, including mutant p53 and E2F1 
that contributed to tumor neo-angiogenesis [15].  Ear-
lier studies by Jeon et al. indicated that Id4 drives 
brain tumor-initiating cell genesis through cyclin E 
and notch signaling [16].  Interestingly, Liang et al. 
observed that Id4 transcripts were present in both 
GBM and oligodendrogliomas, whereas protein ex-
pression of Id4 was present in reactive and neoplastic 
astrocytes, but not in neoplastic oligodendrocytes 
[26].  This selective expression of Id4 in astrocytes 
requires further investigation to determine whether it 
might be exploited for diagnostic purposes. 
In addition to enhancing our understanding of 
key events in the development of primary brain tu-
mors, Ig4 immunolabeling may provide a pragmatic 
diagnostic tool.  For the surgical pathologist, differen-
tiating glioblastoma from low grade gliomas or 
low-grade gliomas from gliosis is usually 
straightforward based on histologic features; howev-
er, it can be problematic, particularly in the setting of 
small biopsy specimens.  In addition, as noted above, 
Id4 immunohistochemistry may provide useful in-
formation for distinguishing oligodendroglial from 
astrocytic tumors.  Accordingly, the confirmation of 
Id4 as a signature biomarker has the potential to in-
crease our diagnostic acumen for this lethal disease. 
In conclusion, our study confirms that Id4 im-
munohistochemistry has a high overall expression in 
GBM, but is less efficacious in separating grade II 
from grade III astrocytoma.  Although these results 
are promising, its limitations should be kept in mind 
when considering Id4 immunohistochemistry for di-
agnostic purposes.  The experience with this antibody 
is still limited and its expression in other glial neop-
lasms and other tumors that can mimic high grade 
astrocytomas has not been systematically studied.   
Based on these findings, additional studies are war-
ranted before the biologic, prognostic or therapeutic 
role of ID4 expression can be firmly established. 
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